Boston Scientific's Breakthrough in Atrial Fibrillation Treatment Propels Stock Surge
Boston Scientific is expected to receive FDA approval for its pulsed field ablation method of treating abnormal heartbeats, which uses electrical pulses to selectively kill problematic cardiac cells. In a comparison with thermal ablation, the newer approach showed similar efficacy and safety profiles. The company's stock surged 6% on the news. Analysts believe that this development positions Boston Scientific to capture a significant share of the nearly $8 billion electrophysiology market.